Most Read Articles
2 days ago
The types of bariatric surgery differentially affect the risk of developing acute pancreatitis postoperatively, such that the risk is greater in patients who undergo vertical sleeve gastrectomy vs Roux-en-Y gastric bypass surgery, according to a study. Risk factors include younger age and presence of gallstones.
6 days ago
Elderly adults using hypoglycaemic glucose-lowering drugs, such as insulin and glinides, have an excess risk of hospitalization for serious trauma, a recent study has found.
6 days ago
Rather than the presence or type or urinary incontinence, increasing severity of urinary incontinence correlates with increased depression, anxiety and stress among treatment-seeking women with lower urinary tract symptoms (LUTS), suggests a study.
Roshini Claire Anthony, 4 days ago

Overweight or obese patients taking lorcaserin as an appetite suppressant may have the added benefit of a reduced risk of incident diabetes, according to results of the CAMELLIA-TIMI 61* trial presented at EASD 2018.

Intravitreous anti-VEGF drugs slightly reduce intraocular pressure

03 May 2018

Intravitreous injections of antivascular endothelial growth factor (anti-VEGF) drugs result in small but statistically significant decrease in intraocular pressure (IOP) over time, a recent database study has shown. Overall, 2.6 percent of eyes have a sustained clinically significant IOP rise compared with 1.5 percent in the fellow untreated eyes, but such an increase is not observed with aflibercept.

Participants were unique patients (n=23,776) who received only a single type of anti-VEGF medication (bevacizumab, aflibercept or ranibizumab) by injection in the right eye in the American Academy of Ophthalmology Intelligent Research in Sight Registry. Included in the subgroups were patients with age-related macular degeneration only and those who had not received anti-VEGF injection for at least 1 year prior to the study.

The authors examined patients with at least 12, 18 and 25 injections for each of the three medications. They used fellow untreated eyes for comparison for all groups. The primary endpoints were the mean change in IOP from baseline at a minimum of 1 year of follow-up and the proportion of eyes with a clinically significant IOP increase, defined as sustained rise of at least 6 mm Hg to an IOP of >21 mm Hg.

IOP decreased from baseline (mean, 0.9 mm Hg in treated eyes vs 0.2 mm Hg in fellow untreated eyes) in all patients in all groups receiving all drugs, showing a statistically significant difference. Bevacizumab was associated with slightly less lowering of IOP than aflibercept and ranibizumab in most subgroups, based on a generalized linear model accounting for confounders.

IOP significantly increased in 2.6 percent of eyes receiving injections compared with 1.5 percent in the associated untreated fellow eyes. The rate by which clinically significant IOP increases occurred was 1.9 percent for aflibercept, 2.8 percent for ranibizumab and 2.8 percent for bevacizumab, which was significantly higher for bevacizumab and ranibizumab, but not aflibercept, than fellow untreated eyes.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
The types of bariatric surgery differentially affect the risk of developing acute pancreatitis postoperatively, such that the risk is greater in patients who undergo vertical sleeve gastrectomy vs Roux-en-Y gastric bypass surgery, according to a study. Risk factors include younger age and presence of gallstones.
6 days ago
Elderly adults using hypoglycaemic glucose-lowering drugs, such as insulin and glinides, have an excess risk of hospitalization for serious trauma, a recent study has found.
6 days ago
Rather than the presence or type or urinary incontinence, increasing severity of urinary incontinence correlates with increased depression, anxiety and stress among treatment-seeking women with lower urinary tract symptoms (LUTS), suggests a study.
Roshini Claire Anthony, 4 days ago

Overweight or obese patients taking lorcaserin as an appetite suppressant may have the added benefit of a reduced risk of incident diabetes, according to results of the CAMELLIA-TIMI 61* trial presented at EASD 2018.